Melsheimer R - Search Results

1

Early Dose Optimisation of Golimumab in Nonresponders to Induction Treatment for Ulcerative Colitis Is Effective and Supported by Pharmacokinetic Data.

Philip G, Cornillie F, Adedokun JO, Melsheimer R, Rutgeerts P, Colombel JF, Marano C. Philip G, et al. Among authors: melsheimer r. J Crohns Colitis. 2019 Sep 27;13(10):1257-1264. doi: 10.1093/ecco-jcc/jjz052. J Crohns Colitis. 2019. PMID: 30847474 Clinical Trial.

2

Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab.

Lin I, Melsheimer R, Bhak RH, Lefebvre P, DerSarkissian M, Emond B, Lax A, Nguyen C, Wu M, Young-Xu Y. Lin I, et al. Among authors: melsheimer r. Curr Med Res Opin. 2022 Apr;38(4):613-627. doi: 10.1080/03007995.2022.2037846. Epub 2022 Feb 18. Curr Med Res Opin. 2022. PMID: 35125053

3

Remicade^® (infliximab): 20 years of contributions to science and medicine.

Melsheimer R, Geldhof A, Apaolaza I, Schaible T. Melsheimer R, et al. Biologics. 2019 Jul 30;13:139-178. doi: 10.2147/BTT.S207246. eCollection 2019. Biologics. 2019. PMID: 31440029 Free PMC article. Review.

4

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab.

Fitzgerald T, Melsheimer R, Lafeuille MH, Lefebvre P, Morrison L, Woodruff K, Lin I, Emond B. Fitzgerald T, et al. Among authors: melsheimer r. Biologics. 2021 Jan 6;15:1-15. doi: 10.2147/BTT.S285610. eCollection 2021. Biologics. 2021. PMID: 33442230 Free PMC article.

5

The Automatic Substitution of Biosimilars: Definitions of Interchangeability are not Interchangeable.

Afzali A, Furtner D, Melsheimer R, Molloy PJ. Afzali A, et al. Among authors: melsheimer r. Adv Ther. 2021 May;38(5):2077-2093. doi: 10.1007/s12325-021-01688-9. Epub 2021 Mar 21. Adv Ther. 2021. PMID: 33745111 Free PMC article. Review.

6

Ensuring Product Quality, Consistency and Patient Supply over Time for a Large-Volume Biologic: Experience with Remicade^®.

Melsheimer R, Calmann M, DeRitis A, Philip V, Van Gog F, Doolittle L, Goyal K, Neblock D. Melsheimer R, et al. BioDrugs. 2018 Oct;32(5):405-414. doi: 10.1007/s40259-018-0300-7. BioDrugs. 2018. PMID: 30143982 Free PMC article. Review.

7

ADHERENCE AND PERSISTENCE TO TREATMENT WITH INFLIXIMAB: ANALYSIS OF A PATIENT SUPPORT PROGRAM COHORT IN BRAZIL.

Branco ABXC, Argolo W, Santos N, Hernandez G, Kakehasi A, Sobrado CW, Melsheimer R. Branco ABXC, et al. Among authors: melsheimer r. Arq Gastroenterol. 2024 May 20;61:e23149. doi: 10.1590/S0004-2803.24612023-149. eCollection 2024. Arq Gastroenterol. 2024. PMID: 38775584 Free article.

8

CA 72-4 radioimmunoassay for the detection of the TAG-72 carcinoma-associated antigen in serum of patients.

Gero EJ, Colcher D, Ferroni P, Melsheimer R, Giani S, Schlom J, Kaplan P. Gero EJ, et al. Among authors: melsheimer r. J Clin Lab Anal. 1989;3(6):360-9. doi: 10.1002/jcla.1860030609. J Clin Lab Anal. 1989. PMID: 2614571

9

Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.

O'Halloran JA, Ko ER, Anstrom KJ, Kedar E, McCarthy MW, Panettieri RA Jr, Maillo M, Nunez PS, Lachiewicz AM, Gonzalez C, Smith PB, de Tai SM, Khan A, Lora AJM, Salathe M, Capo G, Gonzalez DR, Patterson TF, Palma C, Ariza H, Lima MP, Blamoun J, Nannini EC, Sprinz E, Mykietiuk A, Alicic R, Rauseo AM, Wolfe CR, Witting B, Wang JP, Parra-Rodriguez L, Der T, Willsey K, Wen J, Silverstein A, O'Brien SM, Al-Khalidi HR, Maldonado MA, Melsheimer R, Ferguson WG, McNulty SE, Zakroysky P, Halabi S, Benjamin DK Jr, Butler S, Atkinson JC, Adam SJ, Chang S, LaVange L, Proschan M, Bozzette SA, Powderly WG; ACTIV-1 IM Study Group Members. O'Halloran JA, et al. Among authors: melsheimer r. JAMA. 2023 Jul 25;330(4):328-339. doi: 10.1001/jama.2023.11043. JAMA. 2023. PMID: 37428480 Free PMC article.

10

Author's Response to Letter to the Editor - Re: Lin I, Melsheimer R, Bhak RH, et al. Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab. Curr Med Res Opin. 2022;38(4):613-627.

Young-Xu Y, Melsheimer R, Emond B, Lefebvre P, DerSarkissian M, Lax A, Nguyen C, Bhak RH, Wu M, Lin I. Young-Xu Y, et al. Among authors: melsheimer r. Curr Med Res Opin. 2022 Dec;38(12):2237-2240. doi: 10.1080/03007995.2022.2139970. Epub 2022 Nov 7. Curr Med Res Opin. 2022. PMID: 36274636 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13 results

Search Page

Filters